Deficiency of miR-155 in leukemic B-cells results in cell cycle arrest and deregulation of MIR155HG/TP53INP1/CDKN1A/CCND1 network

Golovina E. Kokavec J. Kazantsev D. Yurikova O. Bajecny M. Savvulidi F.G. Simersky R. Lenobel R. Tost J. Herynek V. Sefc L. Sebela M. Klener P. Zemanova Z. Stopka T. Vargova K.S.
April 2025 Elsevier Inc.

Archives of Medical Research
2025 #56 Issue 3

Background: Cell cycle progression and leukemia development are tightly regulated processes in which even a small imbalance in the expression of cell cycle regulatory molecules and microRNAs (miRNAs) can lead to an increased risk of cancer/leukemia development. Here, we focus on the study of a ubiquitous, multifunctional, and oncogenic miRNA-hsa-miR-155–5p (miR-155, MIR155HG), which is overexpressed in malignancies including chronic lymphocytic leukemia (CLL). Nonetheless, the precise mechanism of how miR-155 regulates the cell cycle in leukemic cells remains the subject of extensive research. Methods: We edited the CLL cell line MEC-1 by CRISPR/Cas9 to introduce a short deletion within the MIR155HG gene. To describe changes at the transcriptome and miRNome level in miR-155-deficient cells, we performed mRNA-seq/miRNA-seq and validated changes by qRT-PCR. Flow cytometry was used to measure cell cycle kinetics. A WST-1 assay, hemocytometer, and Annexin V/PI staining assessed cell viability and proliferation. Results: The limited but phenotypically robust miR-155 modification impaired cell proliferation, cell cycle, and cell ploidy. This was accompanied by overexpression of the negative cell cycle regulator p21/CDKN1A and Cyclin D1 (CCND1). We confirmed the overexpression of canonical miR-155 targets such as PU.1, FOS, SHIP-1, TP53INP1 and revealed new potential targets (FCRL5, ISG15, and MX1). Conclusions: We demonstrate that miR-155 deficiency impairs cell proliferation, cell cycle, transcriptome, and miRNome via deregulation of the MIR155HG/TP53INP1/CDKN1A/CCND1 axis. Our CLL model is valuable for further studies to manipulate miRNA levels to revert highly aggressive leukemic cells to nearly benign or non-leukemic types.

B-cells , Cell cycle , CRISPR/Cas9 , Leukemia , miR-155

Text of the article Перейти на текст статьи

Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University, First Faculty of Medicine, Charles University, Vestec, Czech Republic
Al-Farabi Kazakh National University, Faculty of Biology and Biotechnology, Almaty, Kazakhstan
The Center for Advanced Preclinical Imaging, First Faculty of Medicine, Charles University, Prague, Czech Republic
Department of Animal Science, Faculty of Agrobiology, Food and Natural Resources, Czech University, Kamýcká, Prague, Czech Republic
Department of Chemical Biology, Faculty of Science, Palacký University, Olomouc, Czech Republic
Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences and Palacký University, Olomouc, Czech Republic
Centre National de Recherche en Génomique Humaine, CEA-Institut de Biologie Francois Jacob, Universite Paris–Saclay, Évry, France
Department of Biochemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic
Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic

Institute of Pathological Physiology
Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University
Al-Farabi Kazakh National University
The Center for Advanced Preclinical Imaging
Department of Animal Science
Department of Chemical Biology
Laboratory of Growth Regulators
Centre National de Recherche en Génomique Humaine
Department of Biochemistry
Institute of Medical Biochemistry and Laboratory Diagnostics

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026